TY - JOUR
T1 - Long-term expression of von Willebrand factor by a VSV-G pseudotyped lentivirus enhances the functional activity of secreted B-domain-deleted coagulation factor VIII
AU - Park, Sang Won
AU - Choi, Sang Yun
PY - 2007/8/31
Y1 - 2007/8/31
N2 - von Willebrand factor (vWF) is a multimeric glycoprotein which functions within the coagulation system. It colocatizes with factor VIII (FVIII) by non-covalent interaction and alters its intracellular trafficking. vWF is also instrumental in maintaining the stability of secreted FVIII. The principal objective of this study was to generate a lentivirus-based vWF expression vector for gene therapy of hemophilia A. We inserted a vWF of 8.8 Kb into a lentiviral vector thereby producing VSV-G-pseudotyped vEx52. However, its titer was quite low, presumably because the length of vWF gene exceeds the size limit of the lentiviral vector. In order to overcome the low-titer, we concentrated the vEx52 and thus increased the efficiency of transduction approximately 6-fold with 1/100th of the volume. However, as concentration requires an additional laborious step, we attempted to enhance the transduction efficiency by deleting exons 24-46 and 29-46 in pRex52 to construct pRex23 and pRex28, and in pvEx52, yielding pvEx23 and pvEx28, respectively. The transfected. pRex52 had a profound effect on the activity of secreted FVIII, and this activity declined as domains of vWF were deleted. However, when the domain-deleted vWF-lentiviruses were transduced into K562 cells, the vEx28 increased the activity of the secreted FVIII compared to what was observed with vEx52. This result is probably due to higher efficiencies of transduction and expression while retaining the essential domains required for proper interaction with FVIII.
AB - von Willebrand factor (vWF) is a multimeric glycoprotein which functions within the coagulation system. It colocatizes with factor VIII (FVIII) by non-covalent interaction and alters its intracellular trafficking. vWF is also instrumental in maintaining the stability of secreted FVIII. The principal objective of this study was to generate a lentivirus-based vWF expression vector for gene therapy of hemophilia A. We inserted a vWF of 8.8 Kb into a lentiviral vector thereby producing VSV-G-pseudotyped vEx52. However, its titer was quite low, presumably because the length of vWF gene exceeds the size limit of the lentiviral vector. In order to overcome the low-titer, we concentrated the vEx52 and thus increased the efficiency of transduction approximately 6-fold with 1/100th of the volume. However, as concentration requires an additional laborious step, we attempted to enhance the transduction efficiency by deleting exons 24-46 and 29-46 in pRex52 to construct pRex23 and pRex28, and in pvEx52, yielding pvEx23 and pvEx28, respectively. The transfected. pRex52 had a profound effect on the activity of secreted FVIII, and this activity declined as domains of vWF were deleted. However, when the domain-deleted vWF-lentiviruses were transduced into K562 cells, the vEx28 increased the activity of the secreted FVIII compared to what was observed with vEx52. This result is probably due to higher efficiencies of transduction and expression while retaining the essential domains required for proper interaction with FVIII.
KW - Coagulation factor VIII
KW - Gene therapy
KW - Lentivirus
KW - von Willebrand factor
UR - http://www.scopus.com/inward/record.url?scp=35048899179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35048899179&partnerID=8YFLogxK
M3 - Article
C2 - 17846507
AN - SCOPUS:35048899179
SN - 1016-8478
VL - 24
SP - 125
EP - 131
JO - Molecules and cells
JF - Molecules and cells
IS - 1
ER -